Open Nav

Please submit your session questions in advance at

Carmell Therapeutics

  • Randy Hubbell , Carmell Therapeutics

1. Carmell is addressing the burden of healing with its proprietary Plasma-based Bioactive Materials (PBM) technology

a. Carmell is focused on improving patients’ quality of life and reducing costs to the healthcare system

b. Clear FDA regulatory pathway supported by 16+ patent estate

c. Led by strong and seasoned management team backed with category experience in developing and commercializing drug/biologic/drug combination products at leading international pharmaceutical and device companies.

Carmell is employing a rigorous FDA pathway with a Biologic License Application, giving the company the credibility of an FDA-vetted process

Defined BLA pathway provides opportunity with hospital Value Analysis Committees (VACs), who seek proof of efficacy and safety, as well as with potential partners who seek differentiation

Carmell’s novel plasma-based technology is uniquely suited for multiple, high-value indications

  • Date:Monday, February 11
  • Time:1:45 PM - 2:00 PM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23300
  • Goal for Presentation:Educate institutional investors for impending IPO
  • Company
  • Company HQ City:Pittsburgh
  • Company HQ State:Pennsylvania
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$14MM
  • Size of Last Investment Round:$6M
  • Previous and Current Investors:Harbor Light Capital, Newlin Investments, Pittsburgh Life Science Greenshouse
  • CEO/Top Company Official:Randy Hubbell
  • Year Founded:2007
  • Main Therapeutic Focus:Regenerative Medicine
  • Lead Product in Development:Bone Healing Accelerant
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):Dermatology applications (androgenetic alopecia and facial rejuvenation), dental implant and equine.
  • Additional Information/Comments:Carmell is seeking cross over investors to participate in a private round before the planned Spring 2019 IPO. Carmell will begin enrolling in the phase III program in May 2019 with planned last patient in in Q4 2020 and data reveal in Q4 2021.
Randy Hubbell
Carmell Therapeutics